"
Team:EPF-Lausanne/Our Project/Data
From 2011.igem.org
(→Other New parts) |
(→Biobricks) |
||
| Line 37: | Line 37: | ||
==== TetR Mutants ==== | ==== TetR Mutants ==== | ||
| - | + | * V36F mutant: [http://partsregistry.org/Part:BBa_K613013 K613013] | |
| + | * V36F W43S double mutant: [http://partsregistry.org/Part:BBa_K613014 K613014] | ||
| + | * E37A W43S T141A triple mutant: [http://partsregistry.org/Part:BBa_K613015 K613015] | ||
| + | * P39K mutant: [http://partsregistry.org/Part:BBa_K613016 K613016] | ||
| + | * Y42F K108E double mutant: [http://partsregistry.org/Part:BBa_K613018 K613018] | ||
| + | * P39Q Y42M double mutant: [http://partsregistry.org/Part:BBa_K613019 K613019] | ||
| - | === T7 Promoter === | + | ==== T7 Promoter variants ==== |
Our lysis selection device uses what we refer to as the wild-type T7 Promoter: | Our lysis selection device uses what we refer to as the wild-type T7 Promoter: | ||
| Line 74: | Line 79: | ||
[http://partsregistry.org/Part:BBa_K613012 K613012] | [http://partsregistry.org/Part:BBa_K613012 K613012] | ||
| - | = | + | ==== Medium-strength Plac ==== |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | === Medium-strength Plac === | + | |
[http://partsregistry.org/Part:BBa_K613000 K613000] | [http://partsregistry.org/Part:BBa_K613000 K613000] | ||
| - | |||
| - | |||
== Pre-existing parts we improved == | == Pre-existing parts we improved == | ||
Revision as of 02:13, 22 September 2011
Data
team, please check this page: [1]
Contents |
Overview
Summary
There are three pillars that underlie our transcription factor development pipeline. The first pillar is a selection system which lyses cells containing strong matches between a transcription factor and its promoter and allows for the speedy recovery of the relevant DNA. The second pillar is an in vivo characterization system that uses two different reporter systems as a way to document the binding affinities of the TetR transcription factor and its promoter pTet. The third pillar is an in-vitro characterization system called MITOMI that allows for high-throughput analysis of DNA-protein interaction strengths.
In developing these three pillars, a number of parts were made. We have listed all of them and have highlighted our favorites.
Systems
Selection System: We made a T7-promoter-driven lysis device by adding our wildtype T7 promoter () upstream of the Berkeley lysis cassette () inserted in the () plasmid.
In Vivo Characterization:
In Vitro Characterization:
Biobricks
Favourite parts
Pre-existing parts characterised
- Experience - The Berkeley Lysis Device, BBa_K112808: In developing our Lysis selection device, we characterised induction, and ran proof-of-principle experiments.
All other parts submitted
TetR Mutants
- V36F mutant: K613013
- V36F W43S double mutant: K613014
- E37A W43S T141A triple mutant: K613015
- P39K mutant: K613016
- Y42F K108E double mutant: K613018
- P39Q Y42M double mutant: K613019
T7 Promoter variants
Our lysis selection device uses what we refer to as the wild-type T7 Promoter:
In addition, we submitted the following mutants:
Variants without additional lac operator (constitutive):
Variants with additional lac operator (LacI repressed):
Medium-strength Plac
Pre-existing parts we improved
- Experience - The Berkeley Lysis Device, BBa_K112808: In developing our Lysis selection device, we characterised induction, and ran proof-of-principle experiments.
